Although EGFR inhibitors are highly effective for treating EGFR-mutant lung adenocarcinomas (EGFR+ LUADs), resistance inevitably emerges, with histologic transformation to small cell lung cancer (SCLC) representing a particularly aggressive mechanism. Our prospective trial enrolled patients with EGFR+ LUAD at high risk...
L. Morrill Gavarró, Monica F. Chen, Á. Quintanal-Villalonga et al.· Science Translational Medici...· 0 citations
PURPOSE
Mucosal melanoma (MM) is a rare subtype of melanoma with inferior response rates and outcomes to immunotherapy. Vascular endothelial growth factor (VEGF) signaling may contribute to immune resistance and represents a potential therapeutic target. We evaluated nivolumab plus axitinib in untreated, advanced MM in...
S. Lochrin, H. Kalvin, Monica F. Chen et al.· Clinical Cancer Research· 0 citations
Although a heritable component is implicated in ~10% of melanomas, the prevalence and functional relevance of germline pathogenic variants (gPVs) in unselected patients remains unknown. We evaluated 701 patients with melanoma who underwent tumor-normal MSK-IMPACT sequencing (2015–2023) and germline analysis of ≥76 ca...
S. Lochrin, H. Walch, Y. Kemel et al.· npj Genomic Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.